(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Development of Shipping: Controlling Towards a More Associated Future - 2Heat Wave Fuels Massive Wildfire In Australia
- 3Manual for Financial plan Agreeable PC
- 4Who is Artemis? Meet the Greek goddess who inspired NASA's return to the moon
- 5Ford Is Using a Chinese-Built Van to Fight Europe’s EV Price War
- Dental Embed Developments: Upsetting Current Dentistry
- This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- Figure out how to Amplify Your Open Record Reward
- 10 Natural products to Remember for Your Eating routine for a Better You
- Gaza receiving over 70,000 cubic meters of water per day, COGAT claims
- Italy now recognizes the crime of femicide and punishes it with life in prison
- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- Merz: 80% of Syrians in Germany should return in three years
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
